Evidence map›Paper›PMID 38034908›Full record

ArticleFrontiers in digital health2023

NPS MedicineWise application in supporting medication adherence in chronic heart failure: an acceptability and feasibility pilot study.

Jessica Chapman-Goetz, Nerida Packham, Kitty Yu, Genevieve Gabb, Cassandra Potts, Adaire Prosser, Margaret A Arstall, Christine Burdeniuk, Alicia Chan, Teena Wilson and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in digital health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Jessica Chapman-GoetzClinical and Health Sciences, University of South Australia, Adelaide, SA, Australia.
Nerida PackhamConsumer Medicines Information Services, NPS MedicineWise, Surry Hills, NSW, Australia.
Kitty Yue-Health, NPS MedicineWise, Melbourne, VIC, Australia.
Genevieve GabbDepartment of Cardiology, Noarlunga GP Plus Super Clinic, Adelaide, SA, Australia.
Cassandra PottsSA Pharmacy, Flinders Medical Centre, Bedford Park, SA, Australia.
Adaire ProsserSA Pharmacy, Flinders Medical Centre, Bedford Park, SA, Australia.
Margaret A ArstallDepartment of Cardiology, Northern Adelaide Local Health Network, Adelaide, SA, Australia.
Christine BurdeniukDepartment of Cardiology, Flinders Medical Centre, Bedford Park, SA, Australia.
Alicia ChanDepartment of Cardiology, Royal Adelaide Hospital, Adelaide, SA, Australia.
Teena WilsonIntegrated Cardiovascular Clinical Network, Country Health South Australia, Adelaide, SA, Australia.
Elizabeth HothamClinical and Health Sciences, University of South Australia, Adelaide, SA, Australia.
Vijayaprakash SuppiahClinical and Health Sciences, University of South Australia, Adelaide, SA, Australia.
Flinders Medical Centre · AUUniversity of South Australia · AURoyal Adelaide Hospital · AUWA Country Health Service · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Heart failure (HF) is an increasing global concern. Despite evidence-based pharmacotherapy, associated morbidity and mortality remain high. This study aimed to assess the acceptability, feasibility, and value of the NPS MedicineWise dose reminder app in a tiered, pharmacist-led intervention to address medication non-adherence in patients with HF. Methods: This prospective, single-blinded, randomised controlled trial recruited 55 patients with HF between September 2019 and October 2020. Participants were randomly assigned to either the intervention or control arms. Intervention participants used the app which prompted medication administration at each dosing interval. Control participants received standard care and remained blinded to the app throughout the study. Treatment non-adherence prompted a tiered, pharmacist-led intervention. Comparison of the Self-Efficacy for Appropriate Medication Use Scale (SEAMS) at baseline and 6-months measured the app's value in supporting medication adherence. Secondary outcome measures included self-reported medication knowledge, health-related quality of life, psychological wellbeing, and signs and symptoms of HF. Data were analysed using standard statistical tests with significance set at Results: Approximately half of respondents reported managing HF and medications better by using the MedicineWise app (Tier 1). Most respondents expressed satisfaction with the in-app messages (Tier 2) and pharmacists' phone calls (Tier 3). The intervention participants demonstrated a significant improvement in the SEAMS between baseline and 6-months follow-up. Discussion: It is feasible and potentially of value to use the MedicineWise app with a tiered, pharmacist-led intervention to support medication adherence in patients with HF. Our findings provide clinicians with "real-world" information on the practicality and potential value of using mobile health to support treatment adherence in patients with HF. Trial registration number: Australian New Zealand Clinical Trials Registry Clinical trial registration number: ACTRN12619000289112p (http://www.ANZCTR.org.au/ACTRN12619000289112p.aspx).

Indexed as

heart failuremedication adherencemobile health (mHealth)mobile phone applicationmobile technology

Identifiers

PMID38034908
PMCPMC10684918
OpenAlexW4388705282

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.